Tag results:

EGFR

Role of Non-Coding RNAs in Response of Breast Cancer to Radiation Therapy

[Molecular Biology Reports] The authors provide a summary of current findings on non-coding RNAs (ncRNAs) dysregulation after irradiation and present the function and mechanism of ncRNAs in modulating radiosensitivity or radioresistance of breast cancer cells.

Landscape of Surfaceome and Endocytome in Human Glioma Is Divergent and Depends on Cellular Spatial Organization

[Proceedings of the National Academy of Sciences of the United States of America] The authors developed a platform integrated with a newly curated tumor surfaceome classifier that allowed profiling of primary 3D cultures and intact patient glioma tumors with preserved tissue architecture.

T-Box Transcription Factor 19 Promotes Hepatocellular Carcinoma Metastasis through Upregulating EGFR and RAC1

[Oncogene] Epidermal growth factor (EGF)/EGF receptor (EGFR) signaling upregulated T-box 19 (TBX19) expression via ERK/NF-kB pathway and TBX19 fostered HCC metastasis by enhancing EGFR and Rac family small GTPase 1 (RAC1) expression, which formed an EGF-TBX19-EGFR positive feedback loop.

Development of Asolectin-Based Liposomal Formulation for Controlled and Targeted Delivery of Erlotinib as a Model Drug for EGFR Monotherapy

[Journal of Liposome Research] Investigators developed the liposomal formulation, by ether injection method, comprising erlotinib, a tyrosine kinase EGFR inhibitor, proposed to be targeted through enhanced permeability and retention effect effect against pancreatic cancer.

Numb-PRRL Promotes TGF-β1- and EGF-Induced Epithelial-to-Mesenchymal Transition in Pancreatic Cancer

[Cell Death & Disease] The authors studied the specific function of Numb-PRRL isoform in activated EMT of pancreatic ductal adenocarcinoma, which was distinguished from our previous studies that only focused on the total Numb protein.

Ibrutinib Reverses IL-6-Induced Osimertinib Resistance through Inhibition of Laminin α5/FAK Signaling

[Communications Biology] The authors showed that clinically, plasma interleukin-6 (IL-6) level predicted osimertinib efficacy in epidermal growth factor receptor mutant NSCLC patients.

Popular